Anavex Life Sciences Corp (AVXL)

[Investor2014]

Not really and covered under Safe Habor.

Biotech investors do not as rule expect P2b trials leading to approval and would reasonably assume that the “/3” depends strongly on the details of “met all endpoints…” data.

Details that we haven’t seen and won’t see for another few months that it will take to author, have accepted and peer reviewed by some journal.